These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer]. Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735 [TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: Interfering with abiraterone metabolism to optimize therapy. Thoma C Nat Rev Urol; 2016 Jul; 13(7):370. PubMed ID: 27245501 [No Abstract] [Full Text] [Related]
6. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522 [TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919 [TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683 [TBL] [Abstract][Full Text] [Related]
9. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry. Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP J Pharm Biomed Anal; 2018 May; 154():66-74. PubMed ID: 29533860 [TBL] [Abstract][Full Text] [Related]
10. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914 [TBL] [Abstract][Full Text] [Related]
11. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439 [TBL] [Abstract][Full Text] [Related]
12. CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. Salvi S; Casadio V; Burgio SL; Conteduca V; Rossi L; Menna C; Carretta E; Costantini M; Zoli W; De Giorgi U Int J Biol Markers; 2016 Jul; 31(3):e264-9. PubMed ID: 26954071 [TBL] [Abstract][Full Text] [Related]
13. Correction: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Liu C; Armstrong C; Zhu Y; Lou W; Gao AC Oncotarget; 2024 Oct; 15():677-678. PubMed ID: 39352799 [No Abstract] [Full Text] [Related]
14. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward? Suzman D; Eisenberger M Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214 [No Abstract] [Full Text] [Related]
15. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182 [No Abstract] [Full Text] [Related]
16. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968 [TBL] [Abstract][Full Text] [Related]
17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
18. [Abiraterone acetate(ZYTIGA®)-development and literature review]. Nishimura Y; Mukai H; Suzukawa K; Oyama R Gan To Kagaku Ryoho; 2014 Jul; 41(7):811-6. PubMed ID: 25131865 [TBL] [Abstract][Full Text] [Related]
20. An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. Bertaglia V; Tucci M; Vignani F; Buttigliero C; Aroasio E; Berruti A; Scagliotti GV; DI Maio M Minerva Urol Nefrol; 2017 Aug; 69(4):349-358. PubMed ID: 28008755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]